OSTX · Os Therapies Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - |
| R&D | $7.35M | - | $3.76M | $2.50M | $1.31M | - | $1.21M | $992.9K | $361.8K |
| SG&A | $2.82M | - | $3.12M | $2.34M | $3.69M | - | $1.23M | $522.5K | $268.4K |
| Total Operating Expenses | - | - | - | - | - | - | - | - | - |
| D&A | $695 | - | - | - | $695 | - | - | - | $695 |
| Operating Income | ($10.17M) | - | ($6.88M) | ($4.84M) | ($5.00M) | - | ($622.2K) | ($779.8K) | ($630.2K) |
| Interest Expense | $75.3K | - | - | - | $828.8K | - | $1.35M | $777.7K | $828.8K |
| Income Tax | - | - | - | - | - | - | - | - | - |
| Net Income | ($10.40M) | - | ($6.88M) | ($4.54M) | ($3.88M) | - | ($2.88M) | ($2.51M) | ($1.46M) |
| EPS - Basic | ($0.27) | - | ($0.21) | ($0.19) | ($0.25) | - | ($0.18) | ($0.26) | - |
| EPS - Diluted | ($0.27) | - | ($0.21) | ($0.19) | ($0.25) | - | ($0.38) | ($0.26) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $917.6K | $269.8K | $1.88M | $2.80M | $2.97M | $5.53M | $1.86M | $94.9K | $171.5K |
| Accounts Receivable | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - |
| Accounts Payable | - | $9.94M | $3.37M | $2.70M | $1.62M | $1.66M | $1.77M | $2.92M | $2.80M |
| Current Assets | $917.6K | $332.9K | $2.32M | $3.55M | $4.10M | $5.53M | $1.97M | $1.34M | $790.0K |
| Total Assets | $7.30M | $6.84M | $8.95M | $10.31M | $4.25M | $5.54M | $1.98M | $1.34M | $798.1K |
| Current Liabilities | $16.95M | $11.76M | $4.15M | $3.46M | $3.54M | $4.63M | $2.58M | $28.31M | $24.71M |
| Long-term Debt | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $17.05M | $11.86M | $4.25M | $3.56M | $3.64M | $4.73M | $2.68M | $28.41M | $24.81M |
| Stockholders' Equity | ($10.82M) | ($6.10M) | $3.64M | $4.94M | ($4.19M) | ($5.24M) | ($707.1K) | ($21.27M) | ($25.51M) |
| Retained Earnings | ($77.58M) | ($67.19M) | ($53.73M) | ($46.85M) | ($42.31M) | ($40.40M) | ($35.44M) | ($32.57M) | ($29.52M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.56M) | - | - | - | ($3.44M) | - | - | - | ($641.7K) |
| Investing Cash Flow | - | - | - | - | ($173.6K) | - | - | - | $1.1K |
| Financing Cash Flow | $5.21M | - | - | - | $1.05M | - | - | - | $703.0K |
| CapEx | $150.0K | - | - | - | - | - | - | - | - |
| Free Cash Flow | ($4.71M) | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 |
|---|---|---|---|---|---|---|---|---|---|
| Profitability | |||||||||
| Gross margin | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.45 | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - |
| Return on assets | -142.4% | - | -76.8% | -44.0% | -91.2% | - | -145.4% | -186.6% | -182.8% |
| Return on equity | 96.1% | - | -189.1% | -91.8% | 92.6% | - | 406.6% | 11.8% | 5.7% |
| Return on invested capital | - | - | - | - | - | - | - | - | - |
| Liquidity | |||||||||
| Current ratio | 0.05 | 0.03 | 0.56 | 1.03 | 1.16 | 1.20 | 0.76 | 0.05 | 0.03 |
| Quick ratio | 0.05 | 0.03 | 0.56 | 1.03 | 1.16 | 1.20 | 0.76 | 0.05 | 0.03 |
| Cash ratio | 0.05 | 0.02 | 0.45 | 0.81 | 0.84 | 1.20 | 0.72 | 0.00 | 0.01 |
| Leverage | |||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - |
| Interest coverage | -135.0x | - | - | - | -6.0x | - | -0.5x | -1.0x | -0.8x |
| Equity multiplier | -0.67 | -1.12 | 2.46 | 2.09 | -1.02 | -1.06 | -2.80 | -0.06 | -0.03 |
| Liabilities / Assets | 2.34 | 1.73 | 0.47 | 0.35 | 0.86 | 0.85 | 1.36 | 21.16 | 31.09 |
| Efficiency | |||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - |
| Valuation | |||||||||
| P / E | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 17.2x | 9.6x | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - |
| Growth | |||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -103.4% | - | -1005.7% | -520.5% | -693.3% | - | - | - | - |
| Net income growth (YoY) | -168.2% | - | -139.3% | -81.1% | -165.7% | - | - | - | - |
| EPS growth (YoY) | -8.0% | - | 44.7% | 26.9% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -158.5% | -16.4% | - | - | 83.6% | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing OS Therapies Inc against the 5 most active filers in the same SIC group.